

For personal use only

Managing Director's Report 12 Months to 31 July 2024

24 September 2024



Vision, Values and Purpose Statement

Vision
To optimise the health and development of adults, infants and children.

Values
Respect, Response, Responsibility

Purpose
In collaboration with key market participants, Clover develops customised high value nutritional ingredients that enhance the wellbeing and dietary needs of their customers.

Full Year Performance Highlights

♣ Total full year Revenue
\$62.2m in line with guidance down on the FY23 \$79.9m driven by reduced demand in the Infant formula market

♣ Net Profit after tax
\$1.5m down 76% on FY23 \$6.2m

♣ Operating Expenses
\$12.9m down 6.6% (FY23 \$13.8m) driven by reduced head count, travel, marketing

♣ New products continue to diversify the business

♣ Inventory at **\$29.6m** reduced \$7.3m on FY23 full year

♣ Balance Sheet remains strong with cash of **\$12.2m**

♣ Final dividend declared of **0.75 cent** per share

FY24 Update

For personal use only

- ♣ The second half delivered revenue of \$34.9m (1H \$27.3m) an increase of 28%, and NPAT \$2.1m (1H NPAT -\$0.6m).
- ♣ The last quarter delivered improved orders including those from our Chinese customers.
- ♣ The company's inventory position closed at \$29.6 million a 19.9% reduction on the prior year.
- ♣ Lower sales volumes in the 1HFY24 resulted in reduced manufacturing hours combined with the disposal of aged inventory has impacted the overall reported gross margin.
- ♣ Increased attendance at trade shows and customer visits has enhanced the business's ability to connect with new customers which continues to expand the customer base.
- ♣ Ecuador – completed on time and on budget

Full Year 2024 Results


For personal use only

AUD million	4E Reported 31 Jul 2024	4E Reported 31 Jul 2023
Revenue	\$62.2	\$79.9
EBITDA	\$4.0	\$10.0
NPBT	\$1.9	\$8.4
Tax	(\$0.4)	(\$2.3)
NPAT	\$1.5	\$6.2
EPS	0.9 cps	3.7 cps
ROE (annualised)	2.3%	9.2%

- ♣ Customer engagement remains a key focus with continued trialling of new products to diversify and extend our business offering
- ♣ NPAT impacted by lower sales and slowed production with continued investment in new market development supporting future growth and mitigating supply chain risk
- ♣ NPAT result \$1.5m (FY23 \$6.2m)

1st Half & 2nd Half Performance

Net Sales Revenue FY23 and FY24



FY24

1H

- ♣ Market demand fell – high inventory and ongoing low birth rates
- ♣ China moved to algal powders v tuna

FY23

1H

- ♣ driven by stock build ahead of China licensing which came into effect Feb 23
- ♣ Middle East customers grew through brand and market growth

2H

- ♣ Demand reduced following stock build and introduction of China GB license

FY24

2H

- ♣ Excess inventory has been exited improving demand
- ♣ China tuna powder orders returned
- ♣ Western manufacturers have made strong gains through online channels

For personal use only

Balance Sheet 31 July 2024

For personal use only

AUD	Reported 31 Jul 2024 \$M	Reported 31 Jul 2023 \$M	Movement \$M
Cash	12.3	9.4	2.9
Trade Receivables	13.7	12.0	1.7
Inventories	29.6	36.9	(7.3)
Total Current Assets	56.9	60.0	(3.1)
Fixed Assets	27.5	26.2	1.3
Total Assets	84.4	86.2	(1.8)
Trade Payables	(5.1)	(4.6)	0.5
Current Borrowings	(3.4)	(1.7)	1.7
Total Current Liabilities	(9.8)	(8.3)	1.5
Non-Current Borrowings	(5.0)	(7.7)	(2.7)
Total Liabilities	(17.3)	(19.1)	(1.8)
Net Assets	67.1	67.1	(0.0)

- ♣ Tighter inventory control in line with general demand generated a strong cash position at the end of the year.
- ♣ A strong quarter to finish the FY24 year created the higher receivables close.
- ♣ Trade payables decreased in line with timing of raw material purchases, lower demand, offset by a one off non trade settlement (insurance)


Melody Dairies - New Zealand

❖ Melody Dairies remains a strategic investment for Clover.

❖ The ownership structure changed during the year with Food Innovation Waikato selling to Clover and Landcorp. Clover now holds 43.9%. Landcorp will reduce its holding over time selling its interest to its related entity in Spring Sheep who acquired a 12% stake in July 2024.

❖ Under a new management structure and the addition of Spring Sheep as a shareholder the business has operated profitably in the final quarter of FY24.

❖ Clover recognised its share of the full-year Melody loss in the P&L of \$0.5m.



Ecuador

- ♣ AUD 5.0m strategic investment
- ♣ Extraction of fish oil from heads of Tuna
- ♣ Vertical integration, part of the Company's long-term strategy
- ♣ Supply chain protection and risk mitigation
- ♣ Cost reduction



For personal use only

An Update on Growth Platforms

For personal use only



Growth Platform

New products driving future growth

Choline

- ❖ Clover has filed for IP of its unique Choline powder which is to be branded CholineXcel
- ❖ Clover completed a production trial in August 2024 from which the product will be made available for customers to test over the coming months
- ❖ Choline is used in prenatal products and is a required ingredient in infant formula with a current market value of ~ \$150m
- ❖ Use of the unique Choline powder in dry blending operations will overcome the manual handling challenges experienced today



CholineXcel

New
Product
Development

For personal use only

Growth Platform

New products driving future growth



For personal use only

New products

- ♣ Generated meaningful sales across food, gummies, powdered drinks and nutraceuticals.
- ♣ Gelphorm – a major USA brand has incorporated Gelphorm into its UHT product and remains on trial with other UHT customers in the USA & Asia.

Premneo

- ♣ Regulators required a review of all available clinical trials involving DHA and Preterm infants to prove safety; the study has been completed after 12 months and is now under review by clinical experts.
- ♣ Clover is confident the conclusions of the study will pave the way for regulatory approvals.
- ♣ Discussions with potential partners will recommence with regulatory approvals in place.

Gelphorm®

 **Premneo®**

**New
Product
Development**

Growth Platform

Infant formula

Focus on
Infant
Formula

- ♣ The infant formula market globally remains subdued due to lower birth rates
- ♣ Clover's unique powders have allowed customers to achieve higher levels of DHA and meet ingredients requirements adding revenue in H2 FY24
- ♣ The H2 FY24 sales to Chinese manufacturers improved with concerns around Tuna oil abating
- ♣ Online sales have increased in China via the bonded warehouse system improving the sales of Western manufacturers benefiting Clover's demand



For personal use only

FY25 Priorities

Operations & Supply Chain Efficiencies

- ♣ Integration of the Ecuador facility into the supply chain for strategic and gross margin benefits
- ♣ Optimisation and use of Melody Dairies under new management to generate a lower cost of manufacture supporting customer requirements

Innovation & Business Growth

- ♣ Appointment of new distributors to support our sales team in reach and diversification of our segment and customer base
- ♣ Customer engagement in using the free-flowing Choline powder from trial phases to shelf-life testing to commercial sales
- ♣ Achieve regulatory approval for Premneo in ANZ & EU, align with packaging and distribution partners

For personal use only

FY25 Outlook

For personal use only

- ✿ As we move into FY25, Clover aims to build on the demand profile achieved in the second half of FY24
- ✿ Diversification remains a core focus with our powders being used in the nutraceutical markets in addition to major long-term projects including Gelphorm and Premneo providing a channel for growth outside the infant formula market. At the same time, the ability to extend our offering with existing infant formula customers using our unique powdered Choline product is exciting

Disclaimer

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law.

Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor. Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Clover Corporation's current expectations, estimates and projections about the industry in which Clover Corporation operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements.

These statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Clover Corporation, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Clover Corporation cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Clover Corporation only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Clover Corporation will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.